Gilead’s Drugs Harvoni and Sovaldi Prove to Be Safe and Effective in Patients with Advanced Liver Disease Associated with HCV
Hepatitis C, News
Gilead Sciences, Inc. recently announced in a press release the promising results from several Phase 2 clinical trials assessing the use of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) and Sovaldi® (sofosbuvir ... Read more